One of these drugs, liraglutide, can ameliorate kidney fibrosis in a STZ-induced DN model in ED-1 mice by inhibiting TGF-β2-mediated endothelial-mesenchymal transition, a key mechanism that has emerged as an important source of matrix-producing fibroblasts [94]. Here, TGFB2 is linked to liver dysplastic nodule.